Previous 10 | Next 10 |
The U.S. Food and Drug Administration granted orphan drug designation to Syros Pharmaceuticals' (NASDAQ:SYRS) tamibarotene to treat myelodysplastic syndrome (MDS). Tamibarotene is currently being evaluated in combination with azacitidine in a phase 3 trial, dubbed SELECT-MDS-1, to treat&...
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to tamibarotene for the treatment of myelodysplastic syndrome (M...
Initiated Expansion Cohort of SY-5609 with Chemotherapy in Pancreatic Cancer Patients Expects to Report Data from Three Clinical Trials Across Hematology and Selective CDK Inhibitor Programs in 2022 Now Expects to Initiate Phase 1 Single Agent Trial of SY-5609 in Hemat...
Tamibarotene Phase 2 AML data is expected in 2022. Positive trial AML or MDS data would lead to an application to the FDA in 2024. Expanded trials for SY-5609 are getting underway. For further details see: Syros Pharmaceuticals Is A Buy As New Trials Start
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in fireside chats at two upcoming virtual investor conferences. Management will al...
Syros Pharmaceuticals, Inc. (SYRS) Q3 2021 Earnings Conference Call November 5, 2021 8:30 AM ET Company Participants Courtney Solberg - Manager, Corporate Communications Nancy Simonian - President and Chief Executive Officer Jason Haas - Chief Financial Officer David Roth - Chief Medical Offi...
First Patient Dosed in SELECT-AML-1 Trial of Tamibarotene and in Dose Confirmation Study of SY-2101 in APL Presented Phase 1 Data of SY-5609 at ESMO, Demonstrating Clinical Activity at Tolerable Doses and Supporting Development in Three Combination Regimens Expande...
AMCX,AMR,AXL,BBU,BEP,CGAU,CGC,CLMT,CNK,CNTY,D,DKNG,DOC,DTM,EAF,ELAN,ENB,EOG,ERJ,ESNT,FLR,GCI,OTCPK:GCTAF,GECC,GLP,GOOS,GRPN,GT,HE,HMC,INTT,JCI,KIM,LMRK,MFA,MGA,MITT,NMRK,NOG,NWN,OFS,ONCY,PLYM,PNW,REV,SII,SRE,SSP,SYRS,TEN,TRP,TU,TUSK,VRS,VST,VTR,XELA For Seeking Alpha's full earnings season ca...
Syros Pharmaceuticals (NASDAQ:SYRS) is scheduled to announce Q3 earnings results on Friday, November 5th, before market open. The consensus EPS Estimate is -$0.44 (-2.3% Y/Y) and the consensus Revenue Estimate is $4.48M (+17.9% Y/Y). Over the last 2 years, SYRS has beaten EPS estimates 75% of...
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Friday, November 5, 2021 to report its third quarter 2021 financial results and pro...
News, Short Squeeze, Breakout and More Instantly...
Syros Pharmaceuticals Inc. Company Name:
SYRS Stock Symbol:
NASDAQ Market:
Syros Pharmaceuticals Inc. Website:
-- Pivotal Complete Response (CR) Data from SELECT-MDS-1 Phase 3 Trial Expected by Mid-4Q24 -- -- Additional Data from SELECT-AML-1 Phase 2 Trial Expected in September 2024-- -- Management to Host Conference Call at 8:30 AM ET Today -- Syros Pharmaceuticals (NA...
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, July 31, 2024 to report its s...
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...